ストックスクリーナーアプリを入手
9.25
6.08%
0.53
アフターアワーズ：
9.27
0.02
+0.22%
前日終値:
$8.72
開ける：
$8.86
24時間の取引高:
97,773
Relative Volume:
0.36
時価総額：
$740.30M
収益：
-
当期純損益:
$-83.12M
株価収益率:
-6.1844
EPS:
-1.4957
ネットキャッシュフロー:
$-114.50M
1週間 パフォーマンス:
+4.17%
1か月 パフォーマンス:
-10.19%
6か月 パフォーマンス:
-21.74%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$8.86
$9.39
1週間の範囲:
$8.58
$9.5572
52週間の値動き範囲:
$8.58
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
名前
Bridgebio Oncology Therapeutics Inc
セクター
電話
857 702 0377
住所
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
9.25 | 697.89M | 0 | -83.12M | -114.50M | -1.4957 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-11 | 開始されました | Stifel | Buy |
| 2026-01-09 | 開始されました | Raymond James | Outperform |
| 2025-12-05 | 開始されました | Morgan Stanley | Overweight |
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-09-15 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-15 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Bridgebio Oncology Therapeutics Inc (BBOT) 最新ニュース
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform - MSN
Major cancer meeting to feature BridgeBio Oncology KRAS, HER2 data - Stock Titan
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
CFO equity grants at BridgeBio Oncology Therapeutics (BBOT) - Stock Titan
BBOT (BBOT) Chief Scientific Officer receives new stock options and RSU grants - Stock Titan
BridgeBio Oncology (BBOT) awards stock options and RSUs to chief medical officer - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) and Biohaven Ltd. (BHVN) - The Globe and Mail
BBOT: Three next-gen RAS therapeutics show promising efficacy and safety, with key data due in 2026 - TradingView
BBOT: Lead G12C inhibitor and pan-KRAS assets show strong efficacy with key data expected in late 2026 - TradingView
BBOT publishes preclinical data on panKRAS inhibitor BBO-11818 By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Omada Health, Inc. (OMDA) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility - TipRanks
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor - Bitget
BBOT Announces Publication in Cancer Discovery Highlighting - GlobeNewswire
Bridgebio Oncology Therapeutics, Inc. Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is Potent and Selective panKRAS Inhibitor - marketscreener.com
Stifel reiterates Buy on BridgeBio Oncology stock, $23 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on BridgeBio Oncology stock, $23 target - Investing.com South Africa
BBOT reports Q4 2025 results, $425M cash runway into 2028 - National Today
BridgeBio Oncology Therapeutics 10-K: Net loss $134.0M, EPS $(4.30) - TradingView
BridgeBio Oncology Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress - The Manila Times
BBOT Technical Analysis & Stock Price Forecast - Intellectia AI
HLXB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BridgeBio Oncology Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BBOT: Novel RAS-targeted therapies show strong efficacy and safety, with major data readouts expected soon - TradingView
BBOT: Major data from three RAS-focused assets expected in H2, highlighting strong efficacy and safety - TradingView
HLXB SEC FilingsHelix Acqsn II 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga Japan
BBOT to Participate in Upcoming Investor Healthcare Conferences - Bitget
Stifel Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy Recommendation - Nasdaq
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on BridgeBio Oncology Therapeutics With Buy Rating, $23 Price Target - marketscreener.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating - Investing.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com India
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
A Look At BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Momentum - Yahoo Finance
Wells Fargo Remains a Buy on BridgeBio Pharma (BBIO) - Yahoo Finance
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Finviz
BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis - MarketBeat
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) Stock Trends and Sentiment 2026 - MarketBeat
BBOT: Robust efficacy and safety data position these assets as leaders in KRAS-targeted cancer therapy - TradingView — Track All Markets
Bridgebio Oncology Therapeutics Inc (BBOT) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):